Cargando…

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse

BACKGROUND: Tumor relapse constitutes a major challenge for anti-tumoral treatments, including immunotherapies. Indeed, most cancer-related deaths occur during the tumor relapse phase. METHODS: We designed a mouse model of tumor relapse in which mice transplanted with E7(+) TC1 tumor cells received...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerin, Marion v, Regnier, Fabienne, Thoreau, Maxime, Vimeux, Lene, Benard, Matthieu, Dransart, Estelle, Penny, Hweixian L, Johannes, Ludger, Trautmann, Alain, Bercovici, Nadege
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689071/ https://www.ncbi.nlm.nih.gov/pubmed/33239415 http://dx.doi.org/10.1136/jitc-2020-000996

Ejemplares similares

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site
por: Thoreau, Maxime, et al.
Publicado: (2015)

TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors
por: Guerin, Marion V., et al.
Publicado: (2019)

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression
por: Weiss, Julia M., et al.
Publicado: (2017)

Vaccine-induced tumor regression requires a multi-step cooperation between T cells and myeloid cells at the tumor site
por: Thoreau, Maxime, et al.
Publicado: (2015)

Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
por: Peranzoni, Elisa, et al.
Publicado: (2018)

CXCR6 deficiency impairs cancer vaccine efficacy and CD8(+) resident memory T-cell recruitment in head and neck and lung tumors
por: Karaki, Soumaya, et al.
Publicado: (2021)

Revisiting the role of T cells in tumor regression
por: Bercovici, Nadège, et al.
Publicado: (2012)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells
por: Landolina, Nadine, et al.
Publicado: (2022)

Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
por: Sugiyarto, Gessa, et al.
Publicado: (2023)

Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
por: Liu, Chao, et al.
Publicado: (2021)

TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
por: Park, Miso, et al.
Publicado: (2023)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
por: Ng, Harry Ho Man, et al.
Publicado: (2020)

Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
por: Sun, Mayu, et al.
Publicado: (2021)

Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
por: Aoyama, Shota, et al.
Publicado: (2021)

Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment
por: Pizzolla, Angela, et al.
Publicado: (2022)

Preclinical murine tumor models: A structural and functional perspective
por: Guerin, Marion V, et al.
Publicado: (2020)

IFN-γ treatment protocol for MHC-I(lo)/PD-L1(+) pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential
por: Stifter, Katja, et al.
Publicado: (2020)

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
por: Bergamaschi, Cristina, et al.
Publicado: (2020)

Small molecule AZD4635 inhibitor of A(2A)R signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity
por: Borodovsky, Alexandra, et al.
Publicado: (2020)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
por: Jacoberger-Foissac, Celia, et al.
Publicado: (2020)

Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
por: Gao, Aiqin, et al.
Publicado: (2021)

Activated but impaired IFN-γ production of mucosal-associated invariant T cells in patients with hepatocellular carcinoma
por: Huang, Wenyong, et al.
Publicado: (2021)

Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models
por: van Elsas, Marit, et al.
Publicado: (2020)

Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration
por: Higgs, Emily F, et al.
Publicado: (2022)

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
por: Russick, Jules, et al.
Publicado: (2020)

HDAC9 deficiency promotes tumor progression by decreasing the CD8(+) dendritic cell infiltration of the tumor microenvironment
por: Ning, Yongling, et al.
Publicado: (2020)

Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression
por: Wang, Liang, et al.
Publicado: (2020)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression
por: Prat, Mélissa, et al.
Publicado: (2023)

Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer
por: Zhu, Xudong, et al.
Publicado: (2022)

Tumor cell-induced macrophage senescence plays a pivotal role in tumor initiation followed by stable growth in immunocompetent condition
por: Wada, Haruka, et al.
Publicado: (2023)

Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein
por: Torres, Nicolas, et al.
Publicado: (2020)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity
por: Subhadarshini, Seemadri, et al.
Publicado: (2023)

The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer
por: Bercovici, Nadège, et al.
Publicado: (2019)

Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts
por: Woolaver, Rachel A, et al.
Publicado: (2021)

Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells
por: Noyes, David, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dossei3e78omthmckk6q61rmgr